Sitagliptin reduces inflammation fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

摘要

Background and PurposeHeart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by co‐morbidities, and its pathophysiology is poorly understood. Several studies suggesting that dipeptidyl peptidase 4 (DPP4) might be involved in the pathophysiology of heart failure have prompted experimental and clinical investigations of DPP4 inhibitors in the cardiovascular system. Here we have investigated whether the DPP4 inhibitor sitagliptin affected the progression of HFpEF independently of its effects on glycaemia.